Pathogenesis of Rebound SIV/HIV Viremia After Antiretroviral Therapy

抗逆转录病毒治疗后反弹 SIV/HIV 病毒血症的发病机制

基本信息

  • 批准号:
    10224630
  • 负责人:
  • 金额:
    $ 5.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-05 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary The purpose of this administrative core is to support high levels of innovation and collaboration, implement research team processes, and assume responsibility for administrative work as the foundational infrastructure enabling the investigators to focus on achieving the scientific goals of this program project, "Pathogenesis of Rebound SIV/HIV Viremia after Antiretroviral Therapy". Progress toward the ultimate goal of eliminating rebound of HIV viremia after stopping early antiretroviral therapy will be accelerated if the experimental strategies of this PPG are informed and actively updated of discoveries from the entire, international HIV research effort. We have proposed creative and feasible mechanisms to assure the active engagement of our entire PPG team with new knowledge and to support nimble re-design of experimental plans with appropriate allocation of resources. The design of the AC uses robust tools for communications and administrative processes with the intent to be economically efficient and reserve resources for experimentation in the scientific projects and non-human primate core. The AC will be led by the PPG Program Director, Dr. Richard D'Aquila, and will address the following three aims: 1) Establish governance structures facilitating maximum research collaboration and productivity, implement processes for effective communications, and promote excellence via critical, productive external review, 2) Assure that PPG investigators function at the edge of discovery by supporting continual evolution of experimental strategy informed by engagement with HIV research advances outside the PPG, and 3) Establish efficient processes for administrative and fiscal management of PPG resources and effort across all performance sites. The AC will use an experienced Program Manager, an Executive Committee of the principal investigators, and an annually-convened Scientific Advisory Board to manage, govern, and review the PPG, respectively. The AC will work with an additional, innovative component to keep PPG research at the edge of discovery - the CORA (Clinical Observation of Rebound after pausing ART) Advisory Team. The CORA Advisory Team (CAT) will bring together leaders from the US Military HIV Research Program investigating early infection in a human cohort in Thailand (the RV 254/SEARCH 010 study), clinicians and clinical investigators from diverse Chicago institutions at the forefront of HIV care, and patients in order to review the newest information in HIV cure and viremia rebound research and plan a human pilot, observational study in years 4-5 of this PPG. AC support of the PPG scientific team and the CAT will accelerate the pace of scientific discovery by strengthening integration, promoting communications, efficiently delivering administrative services, and lowering organizational barriers to allow investigators to productively and interactively advance the scientific aims of this program.
项目摘要 该管理核心的目的是支持高水平的创新和协作, 研究团队流程,并承担行政工作的责任,作为基础设施 使研究人员能够专注于实现本计划项目的科学目标,“发病机制, 抗逆转录病毒治疗后SIV/HIV病毒血症反弹”。在实现消除 如果实验性的抗逆转录病毒治疗停止后,HIV病毒血症的反弹将加速 该PPG的战略被告知并积极更新来自整个国际艾滋病毒/艾滋病领域的发现, 研究工作。我们提出了创造性和可行的机制,以确保我们的国家积极参与, 整个PPG团队的新知识,并支持灵活的重新设计实验计划, 资源配置AC的设计使用了强大的通信和管理工具 目的是经济有效,并为实验保留资源, 科学项目和非人类灵长类核心。AC将由PPG项目总监Richard博士领导 D 'Aquila,并将实现以下三个目标:1)建立治理结构, 研究协作和生产力,实施有效沟通的流程,并促进 通过关键的、富有成效的外部审查实现卓越,2)确保PPG调查人员在 通过支持不断演变的实验策略,通过与艾滋病毒的接触来发现新的发现 PPG之外的研究进展,以及3)建立有效的行政和财政流程 管理所有绩效站点的PPG资源和工作。AC将使用经验丰富的 项目经理,主要研究者的执行委员会,以及每年召开的科学 咨询委员会分别负责管理、治理和审查PPG。空调将与一个额外的, 创新的组成部分,以保持PPG研究在发现的边缘-CORA(临床观察 暂停ART后反弹)顾问团队。CORA顾问团队(CAT)将汇集领导者 来自美国军方HIV研究项目,该项目调查了泰国人群的早期感染(RV 254/25010研究),来自不同芝加哥机构的临床医生和临床研究者处于最前沿 的艾滋病毒护理和病人,以审查在艾滋病毒治愈和病毒血症反弹研究的最新信息 并计划在本PPG的第4-5年进行一项人体试点观察性研究。PPG科学团队的AC支持 CAT将通过加强整合,促进 沟通,有效地提供行政服务,降低组织障碍, 研究人员以富有成效的和互动的方式推进这一计划的科学目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard D'Aquila其他文献

Richard D'Aquila的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard D'Aquila', 18)}}的其他基金

Pathogenesis of Rebound SIV/HIV Viremia after Antiretrovral Therapy
抗逆转录病毒治疗后反弹 SIV/HIV 病毒血症的发病机制
  • 批准号:
    10224629
  • 财政年份:
    2017
  • 资助金额:
    $ 5.93万
  • 项目类别:
Pathogenesis of Rebound SIV/HIV Viremia after Antiretrovral Therapy
抗逆转录病毒治疗后反弹 SIV/HIV 病毒血症的发病机制
  • 批准号:
    10024236
  • 财政年份:
    2017
  • 资助金额:
    $ 5.93万
  • 项目类别:
Cellular Metabolic Reprogramming and Virus Infectivity
细胞代谢重编程和病毒感染性
  • 批准号:
    10224633
  • 财政年份:
    2017
  • 资助金额:
    $ 5.93万
  • 项目类别:
Pathogenesis of Rebound SIV/HIV Viremia after Antiretrovral Therapy
抗逆转录病毒治疗后反弹 SIV/HIV 病毒血症的发病机制
  • 批准号:
    9323662
  • 财政年份:
    2017
  • 资助金额:
    $ 5.93万
  • 项目类别:
Northwestern University Clinical and Translational Science Institute (NUCATS)
西北大学临床与转化科学研究所 (NUCATS)
  • 批准号:
    10162749
  • 财政年份:
    2015
  • 资助金额:
    $ 5.93万
  • 项目类别:
Northwestern University Clinical and Translational Science Institute (NUCATS)
西北大学临床与转化科学研究所 (NUCATS)
  • 批准号:
    10653872
  • 财政年份:
    2015
  • 资助金额:
    $ 5.93万
  • 项目类别:
Developmental Core
发展核心
  • 批准号:
    10155399
  • 财政年份:
    2015
  • 资助金额:
    $ 5.93万
  • 项目类别:
Northwestern University Clinical and Translational Science Institute (NUCATS)
西北大学临床与转化科学研究所 (NUCATS)
  • 批准号:
    10408296
  • 财政年份:
    2015
  • 资助金额:
    $ 5.93万
  • 项目类别:
Northwestern University Clinical and Translational Science Institute (NUCATS)
西北大学临床与转化科学研究所 (NUCATS)
  • 批准号:
    10195329
  • 财政年份:
    2015
  • 资助金额:
    $ 5.93万
  • 项目类别:
Northwestern University Clinical and Translational Science Institute (NUCATS)
西北大学临床与转化科学研究所 (NUCATS)
  • 批准号:
    10158665
  • 财政年份:
    2015
  • 资助金额:
    $ 5.93万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 5.93万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 5.93万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 5.93万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 5.93万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 5.93万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 5.93万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 5.93万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 5.93万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 5.93万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 5.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了